Five Month-Persistent Extrapyramidal Symptoms following a Single Injection of Paliperidone Palmitate: A Case Report

키워드

참고문헌 (18)

1. Ereshefsky L, "Future of depot neuroleptic therapy : pharmacokinetic and pharmacodynamic approaches", J Clin Psychiatry, 45, pp.50~59 (1984)
2. Brissos S, "The role of long-acting injectable antipsychotics in schizophrenia : a critical appraisal", Ther Adv Psychopharmacol, 4, pp.198~219 (2014)
3. Schreiner A, "Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia", Schizophr Res, 169, pp.393~399 (2015)
4. Li H, "Efficacy and safety of oncemonthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an openlabel, prospective, noncomparative study", Neuropsychiatr Dis Treat, 12, pp.15~24 (2015)
5. Kramer M, "Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study", Int J Neuropsychopharmacol, 13, pp.635~647 (2010)
6. Gopal S, "Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone : a posthoc pooled analysis of seven randomized controlled studies", Neuropsychiatr Dis Treat, 9, pp.1381~1392 (2013)
7. Adams CE, "Systematic meta-review of depot antipsychotic drugs for people with schizophrenia", Br J Psychiatry, 179, pp.290~299 (2001)
8. Kapur S, "Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of firstepisode schizophrenia", Am J Psychiatry, 157, pp.514~520 (2000)
9. Gopal S, "Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia", Curr Med Res Opin, 26, pp.377~387 (2010)
10. Samtani MN, "Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, longacting formulation of an atypical antipsychotic", Clin Pharmacokinet, 48, pp.585~600 (2009)
11. iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol, "Psychopharmacology(Berl)", 2002, 42~49
12. Seeman P, "Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors", Mol Psychiatry, 3, pp.123~134 (1998)
13. Owen RT, "Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia", Drugs Today (Barc), 46, pp.463~471 (2010)
14. Si T, "Pharmacokinetics and tolerability of paliperidone palmitate injection in Chinese subjects", Hum Psychopharmacol, 29, pp.203~210 (2014)
15. Cleton A, "A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intra muscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia", J Clin Pharmacol, 54, pp.1048~1057 (2014)
16. Ravenstijn P, "Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study", J Clin Pharmacol, 56, pp.330~339 (2016)
17. 강남인, "Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial", Clinical Psychopharmacology and Neuroscience, 14(3), pp.261~269 (2016), 대한정신약물학회
18. González-Rodríguez A, "Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review", Patient Prefer Adherence, 9, pp.695~706 (2015)

관련 논문AI추천